Panaxium COO Jonathan Balfour presented the company’s precision neurostimulation therapy to direct brain recovery following injury or stroke.
Toronto, Canada, and Aix-en-Provence, France, October 14, 2022 – Bioelectronic medicine company Panaxium is pleased to announce that it has won the 2022 Brain Innovation Days 1st Place Jury Prize at the conference’s pitch competition held in Brussels, Belgium, on October 12, 2022.
Panaxium COO Jonathan Balfour presented the company’s novel precision neurostimulation therapy to direct brain recovery following injury or stroke. The therapy starts with a patented injury assessment tool, which identifies exactly where the injury has occurred, what functions have been disrupted, and identifies optimal remapping location. Panaxium’s iontronic device is built for neurosurgeons and neurologists to “get in and get out” – delivering unprecedented stimulation directly to the cortex, safely, effectively, and selectively, to restore the patient to normalcy.
The Brain Innovation Days is an initiative led by the European Brain Council, a network of key players in the neuroscience space, with a membership encompassing scientific societies, patient organizations, professional societies, and industry partners. The two-day conference (Brussels, Belgium, October 11-12, 2022) brought together leaders in the brain ecosystem to foster dialogue, exchange knowledge, and accelerate investment in research and innovation and facilitate business development and concluded with a pitch competition juried by prominent medtech and neurotech VCs.
“Thank you to Brain Innovation Days jury for this recognition and thank you to all of our fellow finalists for the incredible work you do in this space,” said Dr. Brad Schmidt, CEO and co-founder of Panaxium. “We are incredibly honoured to receive the 2022 Jury Prize and look forward to continuing to develop our therapy and launch human pilot trials in 2023.”
In 2023 Panaxium will launch a pilot trial at hospitals in Paris, France, sponsored by INSERM, the French National Institute of Health and Medical Research and led by renowned neurologist and researcher Dr. Gilles Huberfeld, MD, PhD at the Hôpital Fondation Adolphe de Rothschild and INSERM.
For more information about Panaxium visit www.panaxium.com.
Panaxium SAS is a bioelectronic medicine company aiming to fundamentally change the way neurological disease is treated using the advantages of AI-enabled iontronic devices. The company is comprised of a multidisciplinary team of internationally renowned scientists, including world experts in organic bioelectronics and leaders in the fields of chemistry, materials science, electrical engineering, systems design, electronic engineering, data science, biology, biochemistry, and nanotechnology. Together they are working to solve some of the most difficult and important problems in medicine.